- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04203719
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Cohort 1:Histologically or cytologically confirmed head and neck squamous cell cancer, primary tumor sites including oropharynx, oral cavity, hypopharynx, or larynx.
Cohort 2:Histologically confirmed advanced/metastatic head and neck non-squamous cell cancer failed with standard treatment.
Cohort 3:Histologically confirmed undifferentiated thyroid cancer not suitable for surgery and failed with standard treatment.
Cohort 4:Histologically confirmed small cell lung cancer failed with only one platinum-containing chemotherapy.
Cohort 5:Histologically confirmed stage IIIB to IV non-squamous cell lung cancer failed with standard treatment.
Cohort 6:Histologically confirmed stage IIIB to IV squamous non-small cell lung cancer failed with at least one platinum-containing or other double-drug chemotherapy.
Cohort 7:Histologically confirmed recurrent/metastasis pleural mesothelioma and thymic cancer failed with at least one-line chemotherapy and not suitable for surgery or radiotherapy.
2. 18 years and older; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Life expectancy ≥ 3 months.
3. At least one measurable lesion. 4. Providing tumor specimen obtained by biopsy or surgical sample within 2 years.
5.The main organs function are normally. 6. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
7. Understood and signed an informed consent form.
Exclusion Criteria:
1.Has used anti-angiogenic drugs such as bevacizumab,erlotinib, apatinib, sorafenib, sunitinib, and endothelium or against PD-1, PD-L1 and other related immunotherapeutic drugs.
2.Has brain metastases with symptoms or symptoms control for less than 2 months.
3.Has diagnosed and/or treated additional malignancy within 5 years prior to the first dose.
4.Has multiple factors affecting oral medication. 5.Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
6.Has unrelieved spinal cord compression. 7.Imaging shows that tumors invade large blood vessels. 8. Central lung squamous cell carcinoma with hollow. 9.Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.
10.Has received surgery, or unhealed wounds within 4 weeks before the first dose.
11. Has artery/venous thrombosis prior to the first dose within 6 months. 12. Has drug abuse history that unable to abstain from or mental disorders 13. Has any serious and / or uncontrolled disease. 14. Has received vaccination or attenuated vaccine within 4 weeks prior to the first dose.
15. Hypersensitivity to recombinant humanized anti-PD-1 monoclonal or its components.
16.Has active autoimmune diseases requiring systemic therapy within 2 years prior to the first dose.
17.Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first dose.
18.Has participated in other anticancer drug clinical trials within 4 weeks. 19.According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anlotinib and AK105 injection
AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
|
a multi-target receptor tyrosine kinase inhibitor
AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: up to 96 weeks
|
Percentage of subjects achieving complete response (CR) and partial response (PR).
|
up to 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: up to 96 weeks
|
DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.
|
up to 96 weeks
|
Disease control rate(DCR)
Time Frame: up to 96 weeks
|
Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).
|
up to 96 weeks
|
Progression-free survival (PFS)
Time Frame: up to 96 weeks
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 96 weeks
|
Overall survival (OS)
Time Frame: up to 120 weeks
|
OS defined as the time from the first dose to death from any cause.
Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 120 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ALTN-AK105-II-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Head, Neck and Chest Cancer
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Head and Neck CancerChina
-
Kuwait Cancer Control CenterRecruitingLocally Advanced Head and Neck CancerKuwait
-
Cairo UniversityUnknownLocally Advanced Head and Neck Cancer
-
Southern Europe New Drug OrganizationClinical Trial Unit Ente Ospedaliero CantonaleCompletedAdvanced Head and Neck Squamous Cancer
-
Radiation Therapy Oncology GroupGlaxoSmithKline; NovartisCompletedNon-HPV Locally Advanced Head and Neck CancerUnited States, Canada
-
National and Kapodistrian University of AthensCompletedBiopsy Confirmed Head and Neck Cancer and Tumors of the Chest
-
Jonsson Comprehensive Cancer CenterKate Farms IncRecruitingLocally Advanced Head and Neck CarcinomaUnited States
-
Centre Jean PerrinGroupement Inter-Régional de Recherche Clinique et d'Innovation Auvergne...RecruitingLocally Advanced Head and Neck CarcinomaFrance
-
University of Alabama at BirminghamCompletedLocally Advanced Head and Neck CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedAdvanced Stage Head and Neck CancerUnited States
Clinical Trials on Anlotinib
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina